Literature DB >> 34178598

Intravenous bisphosphonate therapy does not delay fracture healing in inter-trochanteric femur fractures - A randomised controlled study.

Harsh Jalan1, Ramesh Perumal1, Suresh Prabhu1, Sivakumar Palanivelayutham1, Vibhu Krishnan Viswanathan1, S Rajasekaran1.   

Abstract

Hip fractures in elderly are commonly associated with osteoporosis and surgical outcome is influenced by its concurrent management. The purpose of our study is to determine the association between timing of bisphosphonate administration in inter-trochanteric (IT) fractures and fracture healing. Patients with IT fractures (aged≥50 years) and T-score ≤ -1.5 [WHO defines osteopenia as T-score between -1 and -2.5, and osteoporosis as T-score ≤ -2.5 on DEXA scan (which was obtained post-operatively in our cohort)], who underwent proximal femoral nailing were included. Patients were divided into three groups: group 1a-intravenous bisphosphonate {ivBP [zoledronic acid (ZA)]} given within one week, group 1b-ZA at six weeks and group 2-control group. Post-operative radiographs were assessed for reduction parameters [neck-shaft angle, tip-apex distance, reduction variance]. Radiological union was determined using RUSH score and functional outcome (at one year) with Modified Harris Hip Scores. 41 (23 males), 40 (15 males) and 42 (15 males) patients were included in groups 1a, 1b and 2, respectively (no statistical difference in sex distribution among the groups; p = 0.12). Mean age in groups 1a, 1b and 2 was 71.8 ± 8.1, 75.9 ± 8.5 and 72.3 ± 10.6 years (p = 0.09). There was no significant difference in the pattern of injuries (AO classification) among the groups (p = 0.72). Mean time to union in groups 1a, 1b and 2 was 13.7,13.7 and 14.2 weeks, respectively (p = 0.69). Mean time to union in AO types A1, A2 and A3 fractures was 13.2 ± 2.1, 13.7 ± 2.8 and 16.1 ± 4.9 weeks (p = 0.01). We did not observe any association between T-scores and fracture union (hip:p = 0.52, spine:p = 0.93).The functional outcome was similar among groups (p = 0.96). Early administration of ZA did not negatively influence fracture healing in patients undergoing fixation of IT fractures. Among the various other factors analyzed, there was a statistically significant association between the fracture type (AO type A3) and longer time to fracture union.
© 2021 Delhi Orthopedic Association. All rights reserved.

Entities:  

Keywords:  Bisphosphonates; Inter-trochanteric fracture; Osteoporosis; RUSH score; Zoledronic acid

Year:  2021        PMID: 34178598      PMCID: PMC8213889          DOI: 10.1016/j.jcot.2021.06.002

Source DB:  PubMed          Journal:  J Clin Orthop Trauma        ISSN: 0976-5662


  38 in total

1.  Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?

Authors:  T-Y Kim; Y-C Ha; B-J Kang; Y-K Lee; K-H Koo
Journal:  J Bone Joint Surg Br       Date:  2012-07

2.  Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

Authors:  T Mashiba; T Hirano; C H Turner; M R Forwood; C C Johnston; D B Burr
Journal:  J Bone Miner Res       Date:  2000-04       Impact factor: 6.741

3.  Association between timing of zoledronic acid infusion and hip fracture healing.

Authors:  C Colón-Emeric; L Nordsletten; S Olson; N Major; S Boonen; P Haentjens; P Mesenbrink; J Magaziner; J Adachi; K W Lyles; L Hyldstrup; C Bucci-Rechtweg; C Recknor
Journal:  Osteoporos Int       Date:  2010-12-09       Impact factor: 4.507

4.  Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study.

Authors:  S Tuzun; N Eskiyurt; U Akarirmak; M Saridogan; M Senocak; H Johansson; J A Kanis
Journal:  Osteoporos Int       Date:  2011-05-19       Impact factor: 4.507

5.  Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.

Authors:  Tamara D Rozental; Michael A Vazquez; Aron T Chacko; Nworah Ayogu; Mary L Bouxsein
Journal:  J Hand Surg Am       Date:  2009-04       Impact factor: 2.230

Review 6.  Zoledronic acid: a review of its use in the treatment of osteoporosis.

Authors:  Emma D Deeks; Caroline M Perry
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

7.  Fracture reduction with positive medial cortical support: a key element in stability reconstruction for the unstable pertrochanteric hip fractures.

Authors:  Shi-Min Chang; Ying-Qi Zhang; Zhuo Ma; Qing Li; Jens Dargel; Peer Eysel
Journal:  Arch Orthop Trauma Surg       Date:  2015-04-04       Impact factor: 3.067

8.  Do bisphosphonates affect bone healing? A meta-analysis of randomized controlled trials.

Authors:  Deting Xue; Fangcai Li; Gang Chen; Shigui Yan; Zhijun Pan
Journal:  J Orthop Surg Res       Date:  2014-06-05       Impact factor: 2.359

9.  The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis.

Authors:  Ji-Hye Byun; Sunmee Jang; Sumin Lee; Suyeon Park; Hyun Koo Yoon; Byung-Ho Yoon; Yong-Chan Ha
Journal:  J Bone Metab       Date:  2017-02-28

10.  Effects of Zoledronate on Mortality and Morbidity after Surgical Treatment of Hip Fractures.

Authors:  Ömer Cengiz; Gökhan Polat; Gökhan Karademir; Oytun Derya Tunç; Mehmet Erdil; İbrahim Tuncay; Cengiz Şen
Journal:  Adv Orthop       Date:  2016-03-22
View more
  2 in total

Review 1.  Timing of osteoporosis therapies following fracture: the current status.

Authors:  Rajan Palui; Harsh Durgia; Jayaprakash Sahoo; Dukhabandhu Naik; Sadishkumar Kamalanathan
Journal:  Ther Adv Endocrinol Metab       Date:  2022-07-22       Impact factor: 4.435

2.  The role of hypertrophic chondrocytes in regulation of the cartilage-to-bone transition in fracture healing.

Authors:  Joe Kodama; Kevin J Wilkinson; Masahiro Iwamoto; Satoru Otsuru; Motomi Enomoto-Iwamoto
Journal:  Bone Rep       Date:  2022-08-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.